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ABSTRACT
Background: The BRCA1 gene is an important breast-
cancer susceptibility gene. Promoter polymorphisms can
alter the binding affinity of transcription factors, changing
transcriptional activity and may affect susceptibility to
disease.
Methods and Results: Using direct sequencing of the
BRCA1 promoter region, we identified four polymorphisms
c.-2804TRC (rs799908:TRC), c.-2265CRT
(rs11655505:CRT), c.-2004ARG (rs799906:ARG) and
c.-1896(ACA)1R(ACA)2 (rs8176071:(ACA)1R(ACA)2)
present in Hong Kong Chinese. Each polymorphism was
studied independently and in combination by functional
assays. Although all four variants significantly altered
promoter activity, the c.-2265T allele had stronger binding
than the C allele, and the most common mutant
haplotype, which contains the c.-2265T allele, increased
promoter activity by 70%. Risk association first tested in
Hong Kong Chinese women with breast cancer and age-
matched controls and replicated in a large population-
based study of Shanghai Chinese, together totalling
.3000 participants, showed that carriers of the c.-2265T
allele had a reduced risk for breast cancer (combined odd
ratio (OR) = 0.80, 95% CI 0.69 to 0.93; p = 0.003) which
was more evident among women aged >45 years at first
diagnosis of breast cancer and without a family history of
breast cancer (combined OR = 0.75, 95% CI 0.61 to 0.91;
p = 0.004). The most common haplotype containing the
c.-2265T allele also showed significant risk association for
women aged >45 years without a family history of
breast cancer (OR = 0.64, 95% CI 0.46 to 0.89;
p = 0.008).
Conclusion: This comprehensive study of BRCA1
promoter polymorphisms found four variants that altered
promoter activity and with the most significant contribu-
tion from c.-2265CRT, which could affect susceptibility
to breast cancer in the Chinese population. Its significance
in other populations remains to be investigated.
The BRCA1 gene, a tumour suppressor locus in
chromosome 17q12–21, is an autosomal dominant
gene that plays an important role in breast-cancer
risk. Germline mutations in BRCA1 are associated
with approximately 20% of familial breast cancers
in Caucasian women1 and 81% of breast–ovarian
cancer families.2 Women carrying loss-of-function
mutations in BRCA1 have been reported to carry
an 81% lifetime risk of developing breast cancer.3
BRCA1 mutations account for only 5–10% of all
breast cancers.4 Besides germline and somatic
mutations,5 promoter hypermethylation6 7 was
attributed to reduced BRCA1 expression in some
cases of breast cancer, including sporadic cases.8 9
Single-nucleotide polymorphisms (SNPs) in the
promoter region can affect promoter activity as
nucleotide change may alter the binding affinity of
transcriptional factor involved in the regulation of
gene expression.10 11 We hypothesised that poten-
tially functional BRCA1 promoter polymorphisms
could alter transcriptional activity, thus affecting
susceptibility to develop sporadic breast cancer. To
date, no study has comprehensively investigated
the BRCA1 promoter SNPs for their functional
roles and contribution to risk of developing
sporadic breast cancer. Two recent risk association
studies have investigated 4 tagging SNPs12 and 28
SNPs13 spanning the BRCA1 gene. In the study of
Cox et al,12 the tagging SNPs were not located in
the promoter region. Only two promoter SNPs,
c.-2613GRC (rs799907:GRC) and c.-2004GRA
(rs799906:GRA), were included in the study of
Freedman et al.13 However, the minor allele
frequency (MAF) of c.-2613GRC was ,0.6% in
our Chinese population and thus could not be
analysed. To test our hypothesis, polymorphisms
located in the BRCA1 promoter were identified from
the public dbSNP (http://www.ncbi.nlm.nih.gov/
projects/SNP/) database and by resequencing healthy
Chinese people from Hong Kong. Four promoter
polymorphisms c.-2804TRC (rs799908:TRC),
c.-2265CRT (rs11655505:CRT), c.-2004ARG
(rs799906:ARG) and c.-1896(ACA)1R(ACA)2
(rs8176071:(ACA)1R(ACA)2) were studied by in
vitro assays and genotyping. Although each poly-
morphism could affect promoter activity, the con-
tribution was most significant for c.-2265CRT, as
supported by computed prediction of putative tran-
scription factor binding elements, electrophoretic
mobility shift assay (EMSA) and promoter activity
assay. This finding was further supported by genetic
association analysis in two independent case–control
cohorts of Chinese women.
METHODS
Identification of BRCA1 promoter polymorphisms
BRCA1 promoter SNPs were identified from the
dbSNP database (build no 120) at the start of the
study. The BRCA1 genomic reference sequence
(GenBank number U37574) was used with the first
nucleotide upstream of the translation initiation
codon designated as nucleotide -1.14 To identify
DNA variations that may be unique to Chinese
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populations, direct sequencing of the promoter region (1.6 kb
upstream of the transcription start site at the exon 1a of
BRCA1)14 was also performed on 20 healthy Hong Kong
Chinese. A study group of 20 individuals would give at least
87% probability of finding variants of MAF >5%.
Identification of putative transcription factor binding elements
A computer-based search for putative transcription factor
binding elements harboured by the BRCA1 promoter poly-
morphisms was performed using the software TFSEARCH
(V1.3)15 (http://www.cbrc.jp/research/db/TFSEARCH.html).
All putative transcription factors that are unidirectional with
respect to the sense strand sequence of the BRCA1 promoter in
humans were identified.
Electrophoretic mobility shift assay
Nuclear protein extraction (from human cervical cancer (HeLa)
cells) and EMSA were performed as described previously16 with
some modifications. Briefly, double-stranded c.-2804T, c.-
2804C, c.-2265T and c.-2265C oligonucleotide probes (supple-
mentary table 1 online) were 32P-end-labelled and purified by
using MicroSpin G-50 columns (GE Healthcare, Piscataway,
New Jersey, USA). Binding experiments were conducted by
incubating 10 mg nuclear-protein extracts with 0.14 pmol
(400 000 counts/min) of probe at room temperature for
30 minutes. The nuclear proteins and various oligonucleotide
probes were incubated in a binding buffer containing 10 mmol/l
Tris (pH 7.5), 10% glycerol, 5 mg/ml of poly(dI-dC), 10 mg/ml
bovine serum albumin and 1% Nonidet P-40. For competition
experiments, unlabelled oligonucleotide probes were added to
the radiolabelled probe reaction mixture at 25 or 50 times molar
excess before incubation. After electrophoresis, gels were dried
and subjected to autoradiographic analysis. The shifted band
intensity was analysed by Grab-IT image analysis software
(UVP Inc., Upland, California, USA), the final measurement
being averaged from results of two experiments.
Promoter activity assay
Cloning of the BRCA1 promoter
Genomic DNA of individuals homozygous for the two most
common promoter haplotypes, Tc-2804Cc.-2265Ac.-2004(ACA)1
c.-1896
and Cc.-2804Tc.-2265Gc.-2004(ACA)2
c.-1896, were amplified using spe-
cific primers containing the XhoI and HindIII restriction site
linker at the 59 end of the forward and reverse primers
respectively (supplementary table 1). Amplification was carried
out using a Hi-Fi Expand PCR kit (Roche Diagnostics,
Mannheim, Germany) according to the manufacturer’s recom-
mendations. The amplified products were then cloned into
firefly luciferase-reporter pGL3-basic vector (Promega, Madison,
Wisconsin, USA). These two constructs were named pGL3-
basic/BRCA1-2265C (the wild-type haplotype) and pGL3-basic/
BRCA1-2265T (the most common mutant haplotype), and were
verified by sequencing. Based on the pGL3-basic/BRCA1-2265C
haplotype construct, four other promoter mutant constructs for
which each polymorphism in turn was replaced by the mutant
allele, were created by PCR site-directed mutagenesis and cloned
into pGL3-basic vectors. These four additional haplotypes are as
follows: Cc-2804Cc.-2265Ac.-2004(ACA)1
c.-1896, Tc-2804Tc.-2265Ac.-
2004(ACA)1
c.-1896, Tc-2804Cc.-2265Gc.-2004(ACA)1
c.-1896 and Tc-2804Cc.-
2265Ac.-2004(ACA)2
c.-1896 (bold letters show the difference with
respect to pGL3-basic/BRCA1-2265C).
Luciferase reporter assay
HeLa cell lines were used for transient transfection experiments.
The HeLa cells were cultured in Dulbecco’s modified Eagle’s
medium with high glucose (4.5 mg/mL) (Invitrogen, Carlsbad,
California, USA). In total, 8 6104 cells were cultured in dishes
(35 mm diameter) for 24 hours before transfection, then 1 mg of
Luciferase-reporter plasmid and 0.1 mg of Renilla plasmid were
transfected into the cell lines using Lipofectamine 2000
(Invitrogen). After transient transfection for 24 hours, the cells
were harvested and the activity of the promoter constructs
assayed using the Dual-Luciferase Reporter Assay System
(Promega). To determine promoter activity, firefly luciferase
expression levels were normalised against Renilla luciferase
levels. The luciferase expression levels of pGL3-basic/BRCA1-
2265T and each of the four mutant constructs were compared
with that of pGL3-basic/BRCA1-2265C, which was assigned a
relative value of 1. The pGL3-basic plasmid was used as negative
control. Light emission measurements were carried out using an
Infinite 200 reader (Tecan, Durham, North Carolina, USA). The
experiments were performed in three sets of triplicates. Results
were compared using a non-parametric t test.
Study participants
Hong Kong study participants
The protocol was approved by the Institutional Review Boards
of the University of Hong Kong Hospital Authority, and patient
consent was obtained for study participation and blood
collection.
This was a hospital-based sample collection consisting of 416
women with incident breast cancer, recruited during the period
June 2003 to March 2004, from patients attending follow-up
surgical and oncology outpatient clinics at three major public
hospitals in Hong Kong Island (Queen Mary Hospital) and
Kowloon (Queen Elisabeth Hospital and Kwong Wah Hospital).
All participants completed face to face interviews and were
unselected for family history. Control participants (n = 399)
matched for age at 10-year intervals were recruited from
outpatients attending the general gynaecological clinic in
Queen Mary Hospital who had no personal history of cancer.
They were also questioned about any family history of breast
and/or ovarian cancer. About 70% of cases and controls
interviewed agreed to participate in this project. Blood samples
were obtained from 380 (91.3%) cases and 390 (97.7%) controls,
which were subsequently used for DNA extraction by proteinase
K digestion followed by conventional phenol–chloroform–
ethanol extraction.
Shanghai study participants
The protocol for this study was approved by the relevant ethics
committee.
This was a population-based case-control sample set consist-
ing of participants recruited from 1996 to 1998 by the Shanghai
Breast Cancer Study group. Detailed study methods and
recruitment have been published previously.17 18 The study
comprised 1459 incident breast cancer cases diagnosed at 25–
64 years of age and 1556 age-frequency-matched community
controls. The cancer cases were unselected for family history.
Blood samples were obtained from 1193 (82%) cases and 1310
(84%) controls who consented to participate in the study and
completed the face to face interviews. DNA extraction from the
blood samples were performed as described above.
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Genotyping assays
The c.-2265CRT, c.-2804TRC and c.-2004ARG polymorph-
isms in the Hong Kong participants were genotyped by
denaturing high-performance liquid-chromatography
(DHPLC). The reaction was performed as described previously.19
For the Shanghai study participants, the c.-2265CRT was
assessed using a TaqMan assay (Applied Biosystems, Foster
City, California, USA). Analysis of the c.-1896(ACA)1R(ACA)2
polymorphism was performed by fragment length polymorph-
ism analysis, assessed by GeneScan and GenoTyper software
(Mac OS, Applied Biosystems) as described previously.20 Known
homozygous and heterozygous genotype control samples were
included in each genotyping assay and 5% of test samples for
each 96-well plate reaction were duplicated, with 100%
agreement in genotype obtained. The primers and probes
sequences are listed in supplementary table 1 (online).
Statistical analysis
Hardy–Weinberg equilibrium was investigated using x2 test
(degree of freedom (df) = 1). Odds ratio (OR) and 95%
confidence interval (CI) were used to measure the strength of
association. Genotype and haplotype distribution between cases
and controls were analysed using the x2 test (df = number of
genotypes or haplotypes being analysed minus 1). Two-tailed
tests were used, with p,0.05 considered significant. For the
Shanghai Breast Cancer Study population, additional adjust-
ments were made in logistic regressions for body mass index,
waist to hip ratio, physical activity, education menopausal
status, menarche and age at first live birth. Mantel–Hanzel test
was used to compare the risk association OR between the Hong
Kong and Shanghai groups. Study participants with all
polymorphisms successfully genotyped were included in the
haplotype analysis. The program PLINK V.1.0321 was used for
computational reconstruction of haplotypes. Haplotype fre-
quencies thus obtained were used for haplotype case–control
association analysis. Haploview22 was used for linkage disequili-
brium (LD) analysis to obtain D9 and r2 values. SPSS for
Windows V.15 (SPSS Inc., Chicago, Illinois, USA) was used to
perform non-parametric t test, x2 test and logistic regression
analysis.
RESULTS
At the time the study was started, four promoter SNPs within
the studied BRCA1 promoter region were identified from the
dbSNP database (build 120): c.-2804TRC, c.-2613GRC,
c.-2004ARG, c.-1884ARG (rs3092986:ARG). Direct sequen-
cing of the BRCA1 promoter region in 20 healthy Hong Kong
Chinese identified two previously unreported polymorphisms,
the c.-2265CRT and the c.-1896(ACA)1R(ACA)2 variants,
which have since been included in the dbSNP database. The
c.-2613GRC and c.-1884ARG variants were found to be
monoallelic in these 20 healthy participants and thus were
not included for further study.
The TFSEARCH15 analysis of the c.-2804TRC, c.-2265CRT,
c.-2004ARG and c.-1896(ACA)1R(ACA)2 polymorphisms
showed that c.-2804TRC and c.-2265CRT modified putative
transcription factor recognition motifs with predicted score
differences of >10 between the two alleles (supplementary
table 2). The transcription factors GATA-X (GATA-1,2,3) and
OCT-1 had higher predicted scores for the mutant (minor) allele
of c.-2265CRT. For c.-2804TRC, although Elk-1 had higher
predicted scores for the mutant allele, an opposing transcription
factor, upstream transcription factor (USF), had higher
predicted score for the wild-type allele. In contrast, the putative
transcription factors recognition sequences affected by
c.-2004ARG and c.-1896(ACA)1R(ACA)2, generally scored
.80, none with predicted score differences >10 between the
two alleles.
Electrophoretic mobility shift assay
To investigate whether the mutant alleles of each polymorph-
ism would modify their binding affinity to nuclear protein,
EMSA was performed by incubating HeLa nuclear-protein
extract with double-stranded oligonucleotide probes containing
either allele.
Consistent with the results predicted by TFSEARCH, the
EMSA for c.-2265CRT gave the most clear-cut results.
Upwardly shifted bands found for both alleles could be
competed by excess unlabelled oligonucleotides, with a differ-
ence noted between the C and T probes. For the radiolabelled
C probes (fig 1A, panel a), lanes 3 and 4 (competing with
unlabelled C probe) gave stronger band signals than lanes 5 and
6 (competing with unlabelled T probe), indicating stronger
competition for the unlabelled T probe. Consistent results were
obtained for the radiolabelled T probes (fig 1A, panel b). Lanes
11 and 12 (competing with unlabelled C probe) gave stronger
band signals than lanes 9 and 10 (competing with unlabelled
T probe), indicating again stronger competition for the
unlabelled T probe.
The intensity of the shifted bands was quantified by image
analysis software (fig IB). As the results in panels (a) and (b)
were obtained from separate experiments, an arbitrary relative
value of 1 was assigned for competition with the unlabelled
c.-2265T probe (fig 1A; lanes 5, 6, 9 and 10). For the
radiolabelled C probes (fig 1B, panel a), the relative band
intensity in lanes 3 and 4 (competing with unlabelled C) was
about twice that in lanes 5 and 6 (competing with unlabelled T)
for both concentrations (25 and 50 times, respectively) of
unlabelled probes. For the radiolabelled T probes (fig 1B, panel
b), the relative intensity in lanes 11 and 12 (competing with
unlabelled C) was also about twice that in lanes 9 and 10
(competing with unlabelled T). As a band with greater intensity
corresponds to weaker competition by the unlabelled probe,
these results indicate that c.-2265T has stronger binding to
nuclear proteins than does c.-2265C.
For c.-2804TRC, upwardly shifted bands of either labelled
probe could be competed by the respective cold probe, but not
significantly by the unlabelled probe of the opposite allele,
consistent with the opposing predicted putative transcription
factor scores ascribed for either allele (supplementary fig 1
online). EMSA for c.-2004ARG, c.-1896(ACA)1R(ACA)2 was
unable to clarify their level of contribution to promoter activity,
in keeping with the given putative transcription factors
predicted by TFSEARCH (data not shown).
Promoter activity assays
A luciferase assay was performed to investigate whether each
of these four polymorphisms (c.-2804TRC, c.-2265CRT,
c.-2004ARG and c.-1896(ACA)1R(ACA)2) could alter BRCA1
promoter activity. Frequency estimates of haplotypes using
PLINK had identified two predominant haplotypes occurring in
.94% of Hong Kong cases and controls (supplementary table 3),
which were divergent at all four positions. Six promoter
constructs were created: the wild-type haplotype (named
pGL3-basic/BRCA1-2265C), the predominant mutant haplo-
type (named pGL3-basic/BRCA1-2265T) and haplotypes in
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which one of the polymorphisms in turn was replaced by the
mutant allele.
With the wild-type haplotype as reference, the transcriptional
activity of pGL3-basic/BRCA1-2265T was significantly higher
(fold change of 1.7, p,0.0001, non-parametric t test), support-
ing that notion that the mutant haplotype harbouring the
c.-2265T allele enhances promoter activity (fig 2).
Promoter constructs testing for the contribution of one
polymorphism at a time showed significant difference in
promoter activity for each (p,0.05), suggesting that each of the
four polymorphisms (c.-2804TRC, c.-2265CRT c.-2004ARG,
c.-1896(ACA)1R(ACA)2) could contribute to alteration in pro-
moter activity. Construct IV (Tc-2804Tc.-2265Ac.-2004(ACA)1
c.-1896)
showed that the most significant difference (p = 0.002, fold
change 1.6), followed closely by construct III (Cc-2804Cc.-2265
Ac.-2004(ACA)1
c.-1896) (p = 0.008, fold change 1.6), whereas the other
two constructs contributed to a smaller fold difference in
promoter activity (fold change 1.3) (fig 2), although these
differences remained significant. The higher promoter activity of
the pGL3-basic/BRCA1-2265T corresponds to the higher binding
affinity of the c.-2265T probe to nuclear protein in EMSA.
Genetic association study of BRCA1 promoter variants in Hong
Kong Chinese
To confirm whether these in vitro findings could be shown in
vivo, a genetic association study was carried out on 380 cases
and 390 controls recruited in Hong Kong. Genotyping was
performed for each of the four polymorphisms (c.-2804TRC,
c.-2265CRT, c.-2004ARG, c.-1896(ACA)1R(ACA)2). All gen-
otypes were in Hardy–Weinberg equilibrium for both cases
and controls. Interestingly, only the c.-2265CRT variant
showed significant association for overall genotype
(p = 0.018), minor allele carrier genotype (p = 0.005;
OR = 0.64, 95% CI 0.47 to 0.88) and allele distribution
(p = 0.023; OR = 0.79, 95% CI 0.64 to 0.97) (table 1). For
c.-2804TRC, significant association was noted only for minor
allele carrier genotype (p = 0.036; OR = 0.72, 95% CI 0.53 to
0.98) and allele distribution (p = 0.038; OR = 0.80, 95% CI
0.65 to 0.99), whereas for c.-2004ARG, significant association
was noted for the minor allele carrier genotype only
(p = 0.032; OR = 0.72. 95% CI 0.53 to 0.97). The
c.-1896(ACA)1R(ACA)2) polymorphism showed no signifi-
cant genotype nor allelic association.
Figure 1 (A) EMSA using 28bp double-
stranded oligonucleotides (probes) of the
BRCA1 c.-2265CRT SNP. Lanes 1 and 7:
negative controls (free probe, without
nuclear proteins). Nuclear proteins could
bind to radiolabelled c.-2265C probe (lane
2) and to radiolabelled c.-2265T probe
(lane 8). Competitive binding assay:
addition of increasing molar excess (25
and 50 times, respectively) of non-
radiolabelled probes to radiolabelled (a)
c.-2265C and (b) c.-2265T probes. Lanes
3, 4, 11, 12, competition with non-
radiolabelled C probe; lanes 5, 6, 9, 10,
competition with non-radiolabelled T
probe. White arrows indicate upwardly
shifted bands of the protein–DNA
complexes. (B) Relative intensity of the
shifted bands in the competition assay
shown in (A) for (a) the labelled c.-2265C
probe and (b) the labelled c-2265T probe
(panel b). Lane numbers as before. Bars
are standard deviation.
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Haplotype analysis of the BRCA1 promoter region
Linkage disequilibrium analysis of the four BRCA1 promoter
polymorphisms showed that they were in strong and complete
LD (D9.0.90 and r2.0.85) (supplementary table 4). Frequency
estimates of the haplotypes identified two predominant
haplotypes occurring in .94% of our Hong Kong studied
participants (supplementary table 3). Analysis of the overall
haplotype distribution using PLINK showed significant
Figure 2 Luciferase assay results of the
wild-type (pGL3-basic/BRCA1-2265C)
and mutant BRCA1 promoter haplotype
constructs in HeLa cells. Results are the
means from three independent triplicate
experiments. The luciferase activity
readings of mutant haplotype constructs
were normalised against that of pGL3-
basic/BRCA1-2265C, which was assigned
an arbitrary relative value of 1. Luciferase
levels were significantly higher (p,0.05,
by non-parametric t test) for each mutant
compared with pGL3-basic/BRCA1-2265C
Bars: standard deviation. Constructs I and
II are the wild-type and the predominant
mutant haplotypes respectively, found in
Hong Kong Chinese. Constructs III to VI
were created by site-directed
mutagenesis. Bold and underlined
nucleotides indicate the differences
compared with the wild-type construct.
Table 1 Analysis of BRCA1 promoter polymorphisms c.-2804TRC, c.-2265CRT, c.-2004ARG and
c.-1896(ACA)1R(ACA)2) for breast-cancer risk association in Hong Kong Chinese participants
Polymorphism Genotype/allele
Case Control
p Value OR (95% CI)*n (%) n (%)
c.-2804TRC TT 133 (37.50) 112 (30.10) 0.094{ 1.00 (RV)
TC 169 (47.60) 192 (51.60) 0.071 0.74 (0.54 to 1.03)
CC 53 (14.90) 68 (18.30) 0.059 0.65 (0.42 to 1.02)
TC/CC 222 (62.50) 260 (69.90) 0.036 0.72 (0.53 to 0.98)
T allele 435 (61.30) 416 (55.90) 1.00 (RV)
C allele 275 (38.70) 328 (44.10) 0.038 0.80 (0.65 to 0.99)
HWE p value{ 0.95 0.37
c.-2265CRT CC 143 (38.90) 109 (29.10) 0.018{ 1.00 (RV)
CT 164 (44.60) 197 (52.50) 0.006 0.63 (0.46 to 0.88)
TT 61 (16.60) 69 (18.40) 0.068 0.67 (0.44 to 1.03)
CT/TT 225 (61.10) 266 (70.90) 0.005 0.64 (0.47 to 0.88)
C allele 450 (61.10) 415 (55.30) 1.00 (RV)
T allele 286 (38.90) 335 (44.70) 0.023 0.79 (0.64 to 0.97)
HWE p value{ 0.23 0.22
c.-2004 ARG AA 138 (37.60) 113 (30.10) 0.099{ 1.00 (RV)
AG 171 (46.60) 196 (52.30) 0.041 0.71 (0.52 to 0.99)
GG 58 (15.80) 66 (17.60) 0.135 0.72 (0.47 to 1.11)
AG/GG 229 (62.40) 262 (69.90) 0.032 0.72 (0.53 to 0.97)
A allele 447 (60.90) 422 (56.30) 1.00 (RV)
G allele 287 (39.10) 328 (43.70) 0.070 0.83 (0.67 to 1.02)
HWE p value{ 0.68 0.23
c.-1896
(ACA)1R(ACA)2
(ACA)1(ACA)1 126 (33.60) 118 (30.30) 0.538{ 1.00 (RV)
(ACA)1(ACA)2 185 (49.30) 207 (53.20) 0.276 0.84 (0.61 to 1.15)
(ACA)2(ACA)2 64 (17.10) 64 (16.50) 0.764 0.94 (0.61 to 1.44)
(ACA)1(ACA)2/(ACA)2(ACA)2 249 (66.40) 271 (69.70) 0.333 0.86 (0.63 to 1.17)
(ACA)1allele 437 (58.30) 443 (56.90) 1.00 (RV)
(ACA)2allele 313 (41.70) 335 (43.10) 0.600 0.95 (0.77 to 1.16)
HWE p value{ 0.78 0.09
HWE, Hardy–Weinberg equilibrium; RV, reference value.
*Test of genotype and allele distribution in cases and controls by x2 test (df = 1).
{Test of overall genotype distribution in cases and controls by x2 test (df = 2).
{p Values for HWE were calculated by x2 test, df = 1.
Significant p values are in bold type.
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differences in frequency and composition of haplotypes
between cases and controls (p = 0.001). Risk association
analysis comparing the two predominant haplotypes alone
showed that the association was significant for participants
aged >45 years at diagnosis without a family history of breast
cancer (p = 0.008, OR = 0.64, 95% CI 0.46 to 0.89) (table 2). As
all four polymorphisms were in strong LD, three marker
analyses, in which each polymorphism was excluded in turn,
were performed to identify the contribution of each of the
polymorphisms to risk susceptibility. Analysis of all cases
showed that the exclusion of c.-2265CRT resulted in loss of
haplotype association, suggesting that this SNP contributed
most towards risk association (supplementary table 5). Risk
association remained significant for analysis of participants aged
>45 years at diagnosis without a family history of breast
cancer, regardless of which polymorphism was excluded from
the analyses. This suggests that, consistent with our promoter
activity assay findings, all four polymorphisms contribute in
some way towards risk association.
Risk association analysis of the c.-2265CRT SNP in Hong Kong
and Shanghai participants
Our findings consistently support c.-2265CRT contributing
most towards breast-cancer risk, with genotype data of Hong
Kong participants showing that women with the c.-2265CT/TT
genotype had a significantly reduced breast-cancer risk
(p = 0.005; OR = 0.64, 95% CI 0.47 to 0.88) (table 3), the T
allele acting dominantly.
Early-onset breast cancers, and/or those women with a strong
family history of breast cancer, have a higher likelihood of
harbouring germline mutations in high-penetrance breast-
cancer susceptibility genes. As cases had not been previously
screened for BRCA1 and BRCA2 mutations, stratified analyses
according to age at cancer diagnosis and a family history of
breast cancer were also performed to minimise potential
confounding influence of possible mutations in our analysis,.
As shown in table 3, the association was more pronounced
among women diagnosed at a later age (>45 years) without a
family history of breast cancer (p = 0.006; OR = 0.51, 95% CI
0.32 to 0.81).
To confirm the positive association identified for the
c.-2265CRT SNP in the Hong Kong cohort, we replicated it
on an independent large sample set recruited by the Shanghai
Breast Cancer Study Group. Similar to the results in the Hong
Kong study, a tendency towards a reduced risk was found for
carriers with the c.-2265CT/TT genotypes, which became
significant among women without a family history of breast
cancer (p = 0.019, OR = 0.81, 95% CI 0.69 to 0.97) and among
women aged >45 years at first diagnosis and without a family
history of breast cancer (p = 0.039, OR = 0.79, 95% CI 0.63 to
0.99) (table 3), using logistic regression analysis with adjust-
ment for confounding factors as previously reported18 23
Stratified analysis was performed between the Hong Kong
and Shanghai populations. A test of heterogeneity comparing
the reduced odds ratio did not show significant differences
(p = 0.11) between the two populations, enabling combined
analysis of these two datasets (table 3). The c.-2265CT/TT
genotypes had reduced cancer risk with combined OR = 0.80
(95% CI 0.69 to 0.93) relative to the c.-2265CC genotype, which
was again stronger among older women (aged >45 years at first
diagnosis) without a family history of breast cancer (combined
OR = 0.75, 95% CI 0.61 to 0.91) (table 3).
DISCUSSION
Although some studies have reported promising associations of
cancer risk with the 59 flanking region and promoter poly-
morphisms of several important genes such as oestrogen
receptor-a,24 IGFBP-325 and MMP-2,11 to date there has been
no comprehensive investigation of BRCA1 promoter poly-
morphisms with breast-cancer risk. Changes in transcriptional
regulation of BRCA1 are likely to play an important role in the
initiation or progression of sporadic breast cancer. A consistent
decrease in BRCA1 expression has been found in tumour
samples andepigenetic effects such as aberrant cytosine methy-
lation,6 7 histone hypoacetylation and chromatin condensation26
have been suggested as possible mechanisms in downregulating
BRCA1 expression.
We report, for the first time to our knowledge, a compre-
hensive study of BRCA1 promoter polymorphisms and show
that the common genetic variants c.-2804TRC, c.-2265CRT,
c.-2004ARG and c.-1896(ACA)1R(ACA)2, could affect the
binding affinity of nuclear protein and alter promoter activity.
As supported by computer-based prediction of putative tran-
scription factor binding sites, the contribution of c.-2265CRT
was most significantly shown by EMSA, which showed
stronger binding for the T allele, whereas promoter activity
assay showed that the most common mutant haplotype,
containing the c.-2265T allele, increased promoter activity by
70%. A genetic association study supported this finding,
showing that carriers of the T allele had a reduced risk of
Table 2 Haplotype analysis of the four BRCA1 promoter polymorphisms in relation to breast-cancer risk in
Hong Kong Chinese
c.-2804
TRC
c.-
2265CRT
c.-
2004ARG
c.-1896
(ACA)1R(ACA)2
Cases,
n (%)
Controls*,
n (%) p Value{ OR (95% CI){
All participants (n = 682, n = 734 for cases and controls, respectively){
T C A (ACA)1 394 (57.8) 398 (54.21) RV RV
C T G (ACA)2 253 (37.1) 311 (42.4) 0.076 0.82 (0.66 to 1.02)
Participants without a family history of breast cancer (n = 614, n = 712){
T C A (ACA)1 360 (58.6) 388 (54.5) RV RV
C T G (ACA)2 224 (36.5) 299 (42.0) 0.062 0.81 (0.64 to 1.01)
Participants >45 years at first diagnosis and without a family history of breast cancer (n = 312, n = 322){
T C A (ACA)1 189 (60.6) 169 (52.5) RV RV
C T G (ACA)2 105 (33.7) 146 (45.3) 0.008 0.64 (0.46 to 0.89)
RV, reference value.
*Cancer cases and control participants that had been genotyped for all four promoter single-nucleotide polymorphisms.
{pValues were obtained using x2 test, two-tailed and df = 1
{Haplotype analysis was performed on those participants in which all polymorphisms had been successfully genotyped.
Haplotypes were estimated by PLINK (v1.03).
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breast cancer. This association was stronger among older
women, particularly those without a family history of breast
cancer. Such a pattern of association is expected as germline
mutations in high-penetrance breast-cancer susceptibility genes
are less likely to be found in late-onset cases and in cases
without a family history of breast cancer.27 Moreover, this
finding in Hong Kong Chinese was also replicated in an
independently conducted population-based case–control study
of Shanghai Chinese, which minimises the possibility of type I
error. Meta-analysis of both datasets by the Mantel–Hanzel test
showed no significant difference in reduced ORs between the
two populations, allowing for combined OR analysis, giving a
total of 1484 cases and 1574 controls.
Previous studies had largely focused on association of BRCA1-
coding SNPs. Dunning et al found homozygotes of Arg356 to be
inversely associated with breast-cancer risk,28 but this was not
replicated by Cox et al12 or Freedman et al.13 Cox et al identified
one haplotype associated with a slightly increased risk12 but the
functional variant(s) responsible for this association remains
unknown and promoter SNPs were not included in the analysis.
The multiethnic cohort haplotype analysis performed by
Freedman et al found no significant association between the
common variants of BRCA1 and breast-cancer risk.
Heterogeneity of BRCA1 haplotypes was noted among the
ethnic groups tested, with the haplotypes of Japanese and
Native Hawaiian populations showing relatively lower diversity
and being different from those of African American, Latino and
Caucasian populations.13 Indeed one of the promoter SNPs (c.-
2613GRC) in the study of Freedman et al was monoalleleic in
African Americans, which we also found to be monoallelic in 90
healthy Hong Kong Chinese women (unpublished data). Two
other SNPs (rs1546585 and rs2175957) included by Freedman
are located much further upstream at the 59 end of BRCA1
(18 609 bp and 8805 bp respectively) are unlikely to play an
important role in promoter activity, thus they were not
included in our study. As Thakur and Croce29 had already
shown that a substantial level of promoter activity was
maintained up to –1582 bp, our study included up to 1.6 kb
of the promoter sequence for analysis.
It is noted that another gene, NBR2, is present adjacent to
BRCA1 in a head to head position.30 Indeed the 39 end of the
BRCA1 promoter overlaps with 188 bp of the NBR2 promoter,
with the remaining 59 portion of the BRCA1 promoter
corresponding to the complementary sequence of exon 1 to
partial intron 1 of NBR2. The c.-2265CRT SNP corresponds to
an area 589 nucleotides downstream intron 1 of NBR2 and thus
is less likely to give rise to a functional effect on NBR2
expression or translation.
TFSEARCH identified OCT-1, GATA-1, GATA-2, GATA-3,
USF and Elk-1 as potential transcription factors whose
binding sites spanned the BRCA1 promoter polymorphisms
and therefore could alter their binding affinity. However,
using cotransfection of vectors expressing these putative
factors with pGL3-basic/BRCA1-2265T or pGL3-basic/
BRCA1-2265C we were unable to show any significant
change in the promoter activity assay (data not shown) and
the identity of the transcriptional factors remains to be
investigated.
Although we cannot entirely exclude that the observed
functional effect could be attributed to other variants of
BRCA1 not analysed here, given our promoter assay results
and the strong LD of the polymorphisms in this study,
c.-2265CRT is a most justifiable tagging SNP.
The risk-reduction of 20–25% is consistent with that of a
low-penetrance gene effect. As this SNP (with minor allele
T frequency .35%) is relatively common in the Chinese
population, its use as a predictive marker for reduced cancer
risk is limited. However, as the most common mutant
haplotype (which contains the c.-2265T allele) increased
promoter activity by 70%, the functional consequences of such
higher gene expression in BRCA1, a tumour-suppressor gene,
may indeed confer an important protective role.
Table 3 Association of breast-cancer risk with the c.-2265CRT SNP in the BRCA1 gene, on participants recruited in the Hong Kong Chinese and in
the Shanghai Breast Cancer Study
c.-2265CRT
Hong Kong Shanghai
TOH,
p
Value
Combined analysis{
Cases
(%)
Controls
(%)
p
Value*
OR
(95% CI)*
Cases
(%)
Controls
(%)
p
Value{
OR
95% CI){
p
Value
OR
(95% CI)
All participants1
n 368 375 1109 1185
CC 143 (38.9) 109 (29.1) 1.00 (RV) 469 (42.3) 457 (38.6) 1.00 (RV) 1.00 (RV)
CT/TT 225 (61.1) 266 (70.9) 0.005 0.64
(0.47 to 0.88)
640 (57.7) 728 (61.4) 0.054 0.85
(0.71 to 1.00)
0.11 0.003 0.80
(0.69 to 0.93)
HWE p value" 0.23 0.22 0.07 0.55
Participants without a family history of breast cancer
n 333 363 1070 1156
CC 129 (38.7) 107 (29.5) 1.00 (RV) 459 (42.9) 442 (38.2) 1.00 (RV) 1.00 (RV)
CT/TT 204 (61.3) 256 (70.5) 0.01 0.66
(0.48 to 0.91)
611 (57.1) 714 (61.8) 0.019 0.81
(0.69 to 0.97)
0.23 0.001 0.78
(0.68 to 0.91)
Participants >45 years at first diagnosis and without a family history of breast cancer
n 166 166 637 678
CC 71 (42.8) 46 (27.7) 1.00 (RV) 281 (44.1) 265 (39.1) 1.00 (RV) 1.00 (RV)
CT/TT 95 (57.2) 120 (72.3) 0.006 0.51
(0.32 to 0.81)
356 (55.9) 413 (60.9) 0.039 0.79
(0.63 to 0.99)
0.08 0.004 0.75
(0.61 to 0.91)
HWE, Hardy–Weinberg equilibrium; RV, reference value; TOH, test of heterogeneity.
*p Values were obtained by x2 square test, df = 1.
{Logistic regression analysis adjusted for age, education, body mass index, waist to hip ratio, physical activity, menopausal status, age at menarche and age at first live birth.
{Combined analysis was performed using Mantel–Hanzel test.
1Overall cases and control participants successfully genotyped.
"p Values for HWE were calculated by x2 square test, df = 1.
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In summary, we are the first to show that the common
genetic variants c.-2804TRC, c.-2265CRT, c.-2004ARG and
c.-1896(ACA)1R(ACA)2, can affect the binding affinity of
nuclear proteins and alter promoter activity, with the effect of
c.-2265CRT being most significant. Our genetic association
analysis of two independent Chinese cohorts totalling .3000
participants support these findings by showing that this BRCA1
promoter SNP was significantly associated with reduced
breast-cancer risk. Together with gene expression regulation
by epigenetic mechanisms, promoter polymorphisms may
indeed make an important contribution towards breast-cancer
development.
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